Answers are grounded in this paper and cite their sources.
Sorafenib and sunitinib are inhibitors of tumor angiogenesis have recently generated curiosity regarding its role in cutaneous toxicities, which has severely affected the daily activities resulting in interruption or dose modification of therapy in renal cell carcinoma and hepatocellular carcinomas. We discuss the pathophysiology, adverse cutaneous effects and their grading, potential high risk factors, role of gene polymorphism, critical period of hand-foot skin reaction development and their management.
No takes yet. Share an insight, caveat, or question.
Pragasam et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: